Focused On-demand Library for Epidermal growth factor receptor kinase substrate 8-like protein 2

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.

The compounds are cherry-picked from the vast virtual chemical space of over 60B molecules. The synthesis and delivery of compounds is facilitated by our partner Reaxense.

The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.

Our top-notch dedicated system is used to design specialised libraries.

Fig. 1. The sreening workflow of Receptor.AI

Utilising molecular simulations, our approach thoroughly examines a wide array of proteins, tracking their conformational changes individually and within complexes. Ensemble virtual screening enables us to address conformational flexibility, revealing essential binding sites at functional regions and allosteric locations. Our rigorous analysis guarantees that no potential mechanism of action is overlooked, aiming to uncover new therapeutic targets and lead compounds across diverse biological functions.

Our library distinguishes itself through several key aspects:

The Receptor.AI platform integrates all available data about the target protein, including past experiments, literature data, known ligands, structural information and more. This consolidated approach maximises the probability of prioritising highly relevant compounds.
The platform uses sophisticated molecular simulations to identify possible binding sites so that the compounds in the focused library are suitable for discovering allosteric inhibitors and the binders for cryptic pockets.
The platform integrates over 50 highly customisable AI models, which are thoroughly tested and validated on a multitude of commercial drug discovery programs and research projects. It is designed to be efficient, reliable and accurate. All this power is utilised when producing the focused libraries.
In addition to producing the focused libraries, Receptor.AI provides services and end-to-end solutions at every stage of preclinical drug discovery. The pricing model is success-based, which reduces your risks and leverages the mutual benefits of the project's success.

partner

Reaxense

upacc

Q9H6S3

UPID:

ES8L2_HUMAN

Alternative names:

Epidermal growth factor receptor pathway substrate 8-related protein 2

Alternative UPACC:

Q9H6S3; B3KSX1; B7ZKL3; Q53GM8; Q8WYW7; Q96K06; Q9H6K9

Background:

Epidermal growth factor receptor kinase substrate 8-like protein 2, also known as Epidermal growth factor receptor pathway substrate 8-related protein 2, plays a pivotal role in cellular processes. It is instrumental in stimulating the guanine exchange activity of SOS1, which is crucial for membrane ruffling and the remodeling of the actin cytoskeleton. In the cochlea, it is essential for the maintenance of stereocilia in adult hair cells, highlighting its significance in auditory functions.

Therapeutic significance:

The protein is directly associated with Deafness, autosomal recessive, 106, a form of non-syndromic sensorineural hearing loss. This connection underscores the protein's potential as a target for therapeutic strategies aimed at mitigating or curing sensorineural deafness by addressing the underlying genetic variants affecting its function.